Key result
Cryptotanshinone attenuates pathological hypertrophy and oxidative stress by upregulating SIRT3 and restoring mitochondrial dynamics.
Why the study?
Cryptotanshinone's effects on angiotensin II-induced cardiac hypertrophy and the underlying SIRT3-mediated epigenetic and mitochondrial mechanisms were not fully understood.
Does cryptotanshinone alleviate angiotensin II-induced cardiac hypertrophy in preclinical models?
Does cryptotanshinone alleviate angiotensin II-induced cardiac hypertrophy in preclinical models?
Cryptotanshinone demonstrates potential as a therapeutic candidate for treating cardiac hypertrophy by activating SIRT3-mediated epigenetic regulation and restoring mitochondrial dynamics in preclinical models.
Preclinical effects only; leaves open SIRT3 activation as a hypertrophy target pending human trials.
Cryptotanshinone (CTS), a bioactive diterpenoid extracted from Salvia miltiorrhiza Bunge, has long been recognized as a traditional Chinese herbal compound. This study reveals that CTS exerts potent anti-hypertrophic effects against angiotensin II (Ang II)-induced cardiac hypertrophy by targeting Sirtuin 3 (SIRT3)-mediated epigenetic and mitochondrial pathways. In both in vitro and in vivo models, CTS ameliorated pathological hypertrophy, oxidative stress, inflammation, and apoptosis. Mechanistically, CTS upregulated SIRT3, reducing histone H3K9 acetylation (H3K9ac) and restoring mitochondrial dynamics by balancing fission (DRP1) and fusion (MFN2) proteins. Genetic ablation of SIRT3 exacerbated hypertrophy and mitochondrial dysfunction, while pharmacological inhibition with 3-TYP abolished CTS benefits. These findings elucidate CTS as a therapeutic candidate for cardiac hypertrophy by activating SIRT3, which is accompanied by reduced H3K9ac and restored DRP1/MFN2 balance, highlighting potential in cardiac hypertrophy treatment.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2026) studied Cardiac hypertrophy. Cryptotanshinone (CTS) vs. Ang II-induced hypertrophy models (implied) was evaluated on Pathological hypertrophy, oxidative stress, inflammation, and apoptosis. Cryptotanshinone ameliorated pathological hypertrophy, oxidative stress, inflammation, and apoptosis in vitro and in vivo by upregulating SIRT3 and restoring mitochondrial dynamics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: